The Role of GLI-SOX2 Signaling Axis for Gemcitabine Resistance in Pancreatic Cancer

Oncogene - United Kingdom
doi 10.1038/s41388-018-0553-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Loss of PDPK1 Abrogates Resistance to Gemcitabine in Label-Retaining Pancreatic Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Emodin Reverses Gemcitabine Resistance in Pancreatic Cancer Cells via the Mitochondrial Apoptosis Pathway in Vitro

International Journal of Oncology
Cancer ResearchOncology
2011English

The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-Regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase

Cancer Research
Cancer ResearchOncology
2009English

Role of Protein Kinase D Signaling in Pancreatic Cancer

Biochemical Pharmacology
BiochemistryPharmacology
2010English

Outcomes of Gemcitabine Treatment for Invasive Ductal Pancreatic Cancer

Suizo
2007English

Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine

Clinical Cancer Research
Cancer ResearchOncology
2004English

Microarray Analysis of Circular RNA Expression Profiles Associated With Gemcitabine Resistance in Pancreatic Cancer Cells

Oncology Reports
MedicineCancer ResearchOncology
2018English

The Critical Role and Potential Target of the Autotaxin/Lysophosphatidate Axis in Pancreatic Cancer

Tumor Biology
MedicineCancer Research
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy